First Day Trading

Hutchison China Meditech Limited
19 May 2006



This announcement is not for publication, release or distribution in whole or in
part in Australia, Canada, Japan, the Republic of Ireland, the Republic of South
Africa, the Cayman Islands or the United States.

For Immediate Release                                             19th May 2006


                  Hutchison China MediTech Limited ('Chi-Med')

                          First day of dealings on AIM


Chi-Med announces that admission to trading on AIM will become effective, and
dealings in the ordinary shares of the Company will start, at 8.00am today, 19th
May 2006, under the ticker symbol 'HCM'. The ISIN number will be KYG4672N1016.
Dealings will be conducted in CREST through Depository Interests each
representing an interest in one ordinary share.


Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and focused on researching, developing, manufacturing, and
selling pharmaceuticals, health supplements and other consumer health and
personal care products derived from Traditional Chinese Medicine ('TCM') and
botanical ingredients. Chi-Med's overall aim is to draw on the untapped wealth
of knowledge and history of usage in the TCM industry to develop pharmaceutical
and consumer products for the global market.


On 10th May 2006, Chi-Med announced that it will have raised gross proceeds of
approximately £40 million through a placing with institutional and other
qualified investors and via a Hong Kong Preferential Offering to qualifying
shareholders of Hutchison Whampoa Limited of a total of 14,545,454 new shares at
a price of 275 pence per ordinary share (the 'Placing Price'). Based on that
Placing Price, the market capitalisation of Chi-Med on admission will be
approximately £141 million.


Lazard & Co., Limited is Nominated Advisor to Chi-Med and Panmure Gordon are
Brokers to the Placing.



Contacts
Lazard & Co., Limited
Paul Gismondi
Peter Coupe
Tel: [phone]

Panmure Gordon
Richard Gray
Gilbert Ellacombe
Tel: [phone]

Citigate Dewe Rogerson 
Anthony Carlisle (Mobile: + 44 (0) 7973 611 888)
Chris Gardner
Sarah Gestetner
Tel: [phone]



Lazard & Co., Limited ('Lazard') of 50 Stratton Street, London W1J 8LL, is
acting exclusively for Chi-Med and no-one else in connection with Admission and
the Placing and will not be responsible to anyone other than Chi-Med for
providing the protections afforded to the clients of Lazard, nor for providing
advice in relation to Admission or the Placing, the contents of this
announcement or any transaction, arrangement or other matter referred to herein.

Panmure Gordon (Broking) Limited ('Panmure Gordon'), of 155 Moorgate, London
EC2M 6XB, is acting exclusively for Chi-Med and no-one else in connection with
the Placing and will not be responsible to anyone other than Chi-Med for
providing the protections afforded to the clients of Panmure Gordon, nor for
providing advice in relation to the Placing, the contents of this announcement
or any transaction, arrangement or other matter referred to herein.

This announcement does not constitute an offer of, or the solicitation of an
offer to buy or subscribe for, Ordinary Shares to any person in any jurisdiction
to whom or in which such offer or solicitation is unlawful and, in particular,
is not for release, publication or distribution in or into Australia, Canada,
Japan, The Republic or Ireland, The Republic of South Africa, the Cayman Islands
or the United States.

The offer and sale of the ordinary shares has not been and will not be
registered under the US Securities Act of 1933, as amended (the 'Securities
Act') or under the applicable securities laws of Australia, Canada, Japan, The
Republic or Ireland, The Republic of South Africa or the Cayman Islands. Subject
to certain exceptions, the ordinary shares may not be offered or sold in
Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa,
the Cayman Islands or the United States.





                      This information is provided by RNS
            The company news service from the London Stock Exchange